Abe Posted February 21, 2021 Share Posted February 21, 2021 I am intersted in whether the combination of targeted therapy for MET Exon 14 Skipping (TABRECTA/CAPMATINIB) and immunotherapy (e.g Pembrolizumab/Keytruda) can be better as first line compared to Tabrecta alone. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.